Holen Sie sich die Stockscreener-App
22.98
1.06%
0.24
Handel nachbörslich:
22.76
-0.22
-0.96%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TNDM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$22.74
Offen:
$22.89
24-Stunden-Volumen:
1.04M
Relative Volume:
0.60
Marktkapitalisierung:
$1.43B
Einnahmen:
$796.00M
Nettoeinkommen (Verlust:
$-136.49M
KGV:
-11.00
EPS:
-2.09
Netto-Cashflow:
$-64.24M
1W Leistung:
+6.98%
1M Leistung:
+30.49%
6M Leistung:
-24.90%
1J Leistung:
-47.83%
1-Tages-Spanne:
$22.77
$23.54
1-Wochen-Bereich:
$20.86
$23.54
52-Wochen-Spanne:
$15.75
$53.69
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Firmenname
Tandem Diabetes Care Inc
Sektor
Branche
Telefon
858-366-6900
Adresse
12400 HIGH BLUFF DRIVE, San Diego, CA
Vergleichen Sie TNDM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
22.98 | 1.43B | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Mizuho | Neutral |
| 2025-03-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-03-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-10-04 | Eingeleitet | Goldman | Neutral |
| 2024-10-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Hochstufung | Stifel | Hold → Buy |
| 2023-08-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-05-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-15 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-08-09 | Herabstufung | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Underweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Eingeleitet | Wells Fargo | Overweight |
| 2020-07-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-18 | Bestätigt | Raymond James | Outperform |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-06 | Eingeleitet | Raymond James | Outperform |
| 2020-02-04 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Eingeleitet | Guggenheim | Buy |
| 2019-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2019-05-17 | Bestätigt | BofA/Merrill | Neutral |
| 2019-05-13 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-03-05 | Bestätigt | BofA/Merrill | Neutral |
| 2019-02-27 | Bestätigt | Lake Street | Buy |
| 2018-11-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Bestätigt | Dougherty & Company | Buy |
| 2018-09-26 | Bestätigt | Piper Jaffray | Overweight |
Alle ansehen
Tandem Diabetes Care Inc Aktie (TNDM) Neueste Nachrichten
INVESTOR ALERT: Levi & Korsinsky Notifies Tandem Diabetes Care, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – TNDM - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Notifies Tandem Diabetes Care, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineTNDM - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Tandem Diabetes Care, Inc.(TNDM) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Reminds Tandem Diabetes Care, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2023TNDM - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Reminds Tandem Diabetes Care, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2023 – TNDM - ACCESS Newswire
Diabetes segment reports good news all around - BioWorld MedTech
Tandem Diabetes Care Announces Upcoming Conference Presentations - BioSpace
BlackRock, Inc. Reduces Stake in Tandem Diabetes Care Inc - GuruFocus
Insulin Pump Market Poised for 8.3% CAGR Growth Through 2033 - openPR.com
Earnings Release: Here's Why Analysts Cut Their Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Price Target To US$35.52 - simplywall.st
Tandem Diabetes jumps as overseas sales drive Q1 beat - MSN
Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates - MSN
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q1 2025 Earnings Call Transcript - Insider Monkey
TNDM Stock Rises Despite Q1 Earnings Miss, Gross Margin Up - Yahoo Finance
Tandem Diabetes Care First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Tandem Diabetes Care (TNDM): Analyst Maintains "Buy" Rating and Raises Target Price | TNDM Stock News - GuruFocus
Tandem Diabetes (TNDM) Shares Surge on Robust Q1 Revenue - GuruFocus
Tandem Diabetes Care Reports Record Sales and Strategic Growth - TipRanks
Tandem Diabetes stock jumps on Q1 results (TNDM:NASDAQ) - Seeking Alpha
Tandem Diabetes Care (TNDM) Target Price Lowered by Wells Fargo - GuruFocus
TNDM: Stifel Adjusts Price Target for Tandem Diabetes Care | TND - GuruFocus
TNDM: Piper Sandler Adjusts Price Target Amid Overweight Rating - GuruFocus
TNDM: Baird Maintains Neutral Rating, Lowers Price Target | TNDM Stock News - GuruFocus
Canaccord raises Tandem Diabetes Care target to $59 - Investing.com
Tandem Diabetes Care Stock: A Deep Dive Into Analyst Perspectives (10 Ratings) - Benzinga
Tandem Diabetes (TNDM) Sees Price Target Reduced by Baird | TNDM Stock News - GuruFocus
Tandem Diabetes (TNDM) Price Target Raised by Canaccord Amid Pro - GuruFocus
Tandem Diabetes (TNDM) Target Price Revised as Analysts Remain O - GuruFocus
Tandem Diabetes (TNDM) Price Target Adjusted by Analyst | TNDM S - GuruFocus
Tandem Diabetes Care Inc (TNDM) Q1 2025 Earnings: Revenue Surpas - GuruFocus
Tandem Diabetes Care Inc (TNDM) Q1 2025 Earnings Call Highlights: Record Sales and Strategic ... - Yahoo Finance
Tandem Diabetes Care Reports 22.3% Revenue Increase in Q1 CY2025News and Statistics - IndexBox
Tandem Diabetes Care Inc (TNDM) Q1 2025 Earnings Call Highlights - GuruFocus
Tandem's (TNDM) Strong Q1 Revenue Surpasses Expectations | TNDM Stock News - GuruFocus
Tandem Diabetes Care (TNDM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Tandem Diabetes Care Announces First Quarter 2025 Financial Results - BioSpace
Earnings call transcript: Tandem Diabetes Care Q1 2025 Misses EPS, Stock Rises - Investing.com
Tandem Diabetes’s (NASDAQ:TNDM) Q1: Beats On Revenue, Stock Soars - Yahoo Finance
Tandem Diabetes Q1 2025 slides: dual-platform strategy targets underpenetrated market - Investing.com
Tandem Diabetes (NASDAQ:TNDM) Posts Better-Than-Expected Sales In Q1, Stock Soars - Yahoo Finance
Tandem Diabetes stock surges on revenue beat, strong guidance By Investing.com - Investing.com Nigeria
Tandem Diabetes stock surges on revenue beat, strong guidance - Investing.com Australia
Tandem Diabetes Care Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings Flash (TNDM) Tandem Diabetes Care Reports Q1 Loss $-1.97 Per Share, vs. FactSet Est of $-0.60 - marketscreener.com
Finanzdaten der Tandem Diabetes Care Inc-Aktie (TNDM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):